Arizona State Retirement System Has $814,000 Stock Position in Biohaven Ltd. (NYSE:BHVN)

Arizona State Retirement System raised its position in shares of Biohaven Ltd. (NYSE:BHVN) by 15.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,028 shares of the company’s stock after purchasing an additional 2,517 shares during the period. Arizona State Retirement System’s holdings in Biohaven were worth $814,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Capital World Investors raised its position in Biohaven by 7.5% during the first quarter. Capital World Investors now owns 6,642,539 shares of the company’s stock valued at $787,606,000 after purchasing an additional 464,530 shares in the last quarter. Stifel Financial Corp grew its stake in shares of Biohaven by 2.7% during the third quarter. Stifel Financial Corp now owns 5,769,749 shares of the company’s stock worth $150,071,000 after buying an additional 150,000 shares during the last quarter. BlackRock Inc. grew its stake in shares of Biohaven by 0.5% during the first quarter. BlackRock Inc. now owns 4,656,866 shares of the company’s stock worth $552,163,000 after buying an additional 21,586 shares during the last quarter. State Street Corp grew its stake in shares of Biohaven by 28.0% during the third quarter. State Street Corp now owns 2,233,366 shares of the company’s stock worth $266,638,000 after buying an additional 488,320 shares during the last quarter. Finally, Holocene Advisors LP grew its stake in shares of Biohaven by 1.0% during the second quarter. Holocene Advisors LP now owns 2,063,988 shares of the company’s stock worth $49,371,000 after buying an additional 20,279 shares during the last quarter. 88.78% of the stock is currently owned by institutional investors and hedge funds.

Biohaven Trading Up 1.0 %

Shares of BHVN opened at $44.19 on Thursday. The stock has a market capitalization of $3.61 billion, a P/E ratio of -7.81 and a beta of 1.18. The firm’s fifty day simple moving average is $52.13 and its two-hundred day simple moving average is $41.23. Biohaven Ltd. has a 12 month low of $12.35 and a 12 month high of $62.21.

Biohaven (NYSE:BHVN) last issued its quarterly earnings results on Thursday, February 29th. The company reported ($1.81) EPS for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.40). As a group, research analysts predict that Biohaven Ltd. will post -5.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on BHVN. UBS Group began coverage on shares of Biohaven in a research note on Tuesday, February 6th. They set a “buy” rating and a $59.00 target price on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $61.00 target price on shares of Biohaven in a research note on Tuesday, April 9th. TD Cowen boosted their target price on shares of Biohaven from $35.00 to $55.00 and gave the stock an “outperform” rating in a research note on Friday, March 1st. JPMorgan Chase & Co. boosted their price objective on shares of Biohaven from $32.00 to $56.00 and gave the stock an “overweight” rating in a research note on Friday, February 23rd. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a research note on Wednesday, April 10th. Eight analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $52.00.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.